氟达拉滨联合中剂量阿糖胞苷治疗急性髓系白血病疗效观察  

Curative Effect of Fludarabine Combined With Middle-dose Cytarabine in the Treatment of Acute Myeloid Leukemia

作　　者：周淑秋[1] ZHOU Shuqiu(Geriatric Department,Fourth Hospital of Daqing City,Heilongjiang Province,Daqing Heilongjiang 163000,China)

机构地区：[1]黑龙江省大庆市第四医院老年病科,黑龙江大庆163000

出　　处：《中国卫生标准管理》2022年第4期89-93,共5页China Health Standard Management

摘　　要：目的观察氟达拉滨联合中剂量阿糖胞苷治疗急性髓系白血病(acute myelogenous leukemia,AML)的价值。方法随机将本院2019年1月—2020年1月收治的62例AML分为两组,每组31例。两组均行氟达拉滨方案,对照组行大剂量阿糖胞苷干预,观察组行中剂量阿糖胞苷干预。比较两组的治疗效果。结果(1)治疗后,观察组胰岛素样生长因子(insulin-like growth factor 1,IGF-1)、白血病抑制因子(leukemia inhibitory factor,LIF)水平分别为(96.17±5.54)ng/mL和(96.83±3.86)ng/mL,对照组为(76.28±4.91)ng/mL和(78.37±3.11)ng/mL,两组间差异有统计学意义(P<0.05)。(2)观察组总有效率为93.55%(27/31),明显高于对照组的74.19%(23/31),差异有统计学意义(P<0.05)。(3)观察组不良反应发生率为19.35%(6/31),明显低于对照组的38.71%(12/31),差异有统计学意义(P<0.05)。(4)对照组感染发生率(35.48%)明显高于观察组(12.90%),差异有统计学意义(P<0.05)。(5)治疗后,观察组T淋巴细胞明显高于对照组,差异有统计学意义(P<0.05)。结论氟达拉滨联合中剂量阿糖胞苷的功效理想,不仅促进了症状的缓解及淋巴细胞水平的改善,增强了患者的抵抗力,另外还降低了感染率,增加了用药的安全性,值得推广应用。Objective To observe the value of fludarabine combined with medium-dose cytarabine in the treatment of acute myelogenous leukemia(AML).Methods A total of 62 AML cases admitted to our hospital from January 2019 to January 2020 were randomly divided into two groups,with 31 cases in each group.Both groups were treated with fludarabine,the control group was treated with high-dose cytarabine intervention,and the observation group was treated with middle-dose cytarabine intervention.The two groups of treatment effects were recorded.Results(1)After treatment,the levels of insulin-like growth factor(insulin-like growth factor 1,IGF-1)and leukemia inhibitory factor(LIF)in the observation group were(96.17±5.54)ng/mL and(96.83±3.86)ng/mL,respectively,while the control group were(76.28±4.91)ng/mL and(78.37±3.11)ng/mL,the differences between the two groups were statistically significant(P<0.05).(2)The total effective rate of the observation group was 93.55%(27/31),which was significantly higher than 74.19%(23/31)of the control group,the difference was statistically significant(P<0.05)(3)The adverse reaction rate of the observation group was 19.35%(6/31),which was significantly lower than 38.71%(12/31)of the control group,the difference was statistically significant(P<0.05).(4)The incidence of infection in control group(35.48%)was significantly higher than that in observation group(12.90%),and the difference was statistically significant(P<0.05).(5)After treatment,T lymphocytes in the observation group were significantly higher than those in the control group(P<0.05).Conclusion Fludarabine combined with medium-dose cytarabine has ideal efficacy,which not only promotes the relief of symptoms and the improvement of lymphocyte level,but also enhances the resistance of patients,reduces the infection rate,increases the safety of medication.Therefore,it is worthy of popularization and application.

关 键 词：氟达拉滨 AML 阿糖胞苷 化疗 中剂量 淋巴细胞 

分 类 号：R551[医药卫生—血液循环系统疾病]